Akèy › Sipwa › North Carolina

Etid klinik pou Sipwa nan North Carolina

40 etid pou Sipwa ap chèche patisipan nan sit nan North Carolina.

Vil nan North Carolina

Tèks ofisyèl etid la (Anglè)

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Medication Management /ID# 281965, Greensboro
Monroe Biomedical Research /ID# 282009, Monroe
Centricity Research - Morehead city /ID# 283264, Morehead City
ak 2 plis

Ap rekriteFaz 2

Laj 18 a 75 · Tout sèks · Mizajou Oct 1, 2026 · NCT07752979

FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing)

University of North Carolina at Chapel Hill, Chapel Hill

Ap rekrite

Laj 18 a 75 · Tout sèks · Mizajou Sep 29, 2026 · NCT06724406

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

Medication Mgmnt, LLC_Grnsboro, Greensboro
Accellacare of Raleigh, Raleigh
Accellacare-Salisbury PMG Res, Salisbury
ak 1 plis

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07720271

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

PharmQuest Life Sciences LLC, Greensboro
Piedmont Healthcare/Research, Statesville

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07668414

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

TMA Headlands, Wilmington

Ap rekriteFaz 2

Laj 18 a 75 · Tout sèks · Mizajou Sep 28, 2026 · NCT07837973

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Medication Management, Greensboro
Monroe Biomedical Research, Monroe
West Clinical Research, Morehead City
ak 1 plis

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07794579

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

Medication Management, LLC, Greensboro
Accellacare - Wilmington, Wilmington
Jeffrey Coleman, OD, Wilmington

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07595549

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

Research Site, Statesville

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07776509

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

UNC Children's Hospital, Chapel Hill
Duke Children's Primary Care, Durham
Lucas Research, Inc, Morehead City

Ap rekriteFaz 3

Laj 6 a 17 · Tout sèks · Mizajou Sep 24, 2026 · NCT06672549

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Coastal Research Institute - Fayetteville, Fayetteville

Ap rekriteFaz 3

Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT06937099

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Coastal Research Institute - Fayetteville, Fayetteville

Ap rekriteFaz 3

Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT06937086

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

Monroe Biomedical Research, Monroe

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07321886

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Novant Health Heart and Vascular Institute, Charlotte
Velocity Clinical Research - Durham, Durham
Moses H Cone Memorial Hospital, Greensboro
ak 7 plis

Ap rekriteFaz 3

Laj 45 a 99 · Tout sèks · Mizajou Sep 22, 2026 · NCT07037433

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

University of North Carolina Medical Center, Chapel Hill
Medication Management, Greensboro
Carteret Medical Group, Morehead City
ak 1 plis

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07392190

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Medication Management, Greensboro
Monroe Biomedical Research, Monroe
Lucas Research, Inc, Morehead City
ak 1 plis

Ap rekriteFaz 2

Laj 18 a 75 · Tout sèks · Mizajou Sep 22, 2026 · NCT07589608

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

PharmQuest Life Sciences, LLC, Greensboro
West Clinical Research, Morehead City
Trial Management Associates - Wilmington - Floral Parkway, Wilmington

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07282600

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

Research Site, Monroe

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07784270

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

AURORA-1 Clinical Site, Charlotte
AURORA-1 Clinical Site, Greenville
AURORA-1 Clinical Site, Morehead City
ak 1 plis

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07743463

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

AURORA-2 Clinical Site, Charlotte
AURORA-2 Clinical Site, Durham
AURORA-2 Clinical Site, Greenville
ak 2 plis

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07743450

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

Centricity Research Morehead City Multispeciality, Morehead City
Wake Forest University Health Sciences, Winston-Salem

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT07351058

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Lucas Research, Inc., Morehead City
Shelby Clinical Research, Shelby

Ap rekriteFaz 2

Laj 18 a 75 · Tout sèks · Mizajou Sep 14, 2026 · NCT06897475

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

ACCOMPLISH-2 Research Site, Charlotte
ACCOMPLISH-2 Research Site, Durham
ACCOMPLISH-2 Research Site, Fayetteville
ak 2 plis

Ap rekriteFaz 3Volontè an sante akeyi

Laj 18 a 79 · Tout sèks · Mizajou Sep 11, 2026 · NCT07654374

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Medication Management, Greensboro
Monroe Biomedical Research, Monroe
Lucas Research, Inc, Morehead City
ak 1 plis

Ap rekriteFaz 2

Laj 18 a 75 · Tout sèks · Mizajou Sep 8, 2026 · NCT06143956

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

PharmQuest, Greensboro
KDCILM, LLC & Accellacare US, Inc., Wilmington

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT07745504

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

Revival Research Institute, LLC, Cary
Onsite Clinical Solutions - Huntersville, Huntersville

Ap rekriteFaz 4

Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06857942

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

Kailera Clinical Site, Morehead City

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07284875

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Accellacare of Hickory, Hickory
Carolina Research Center Inc, Shelby

Ap rekriteFaz 3

Laj 18 a 99 · Tout sèks · Mizajou Sep 3, 2026 · NCT07684235

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

West Clinical Research, Morehead City

Ap rekriteFaz 3

Laj 18 a 99 · Tout sèks · Mizajou Sep 3, 2026 · NCT07684144

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Kailera Clinical Site, Greensboro
Kailera Clinical Site, Monroe
Kailera Clinical Site, Morehead City
ak 1 plis

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07284901

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Centricity Research Morehead City Specialty, Morehead City
Accellacare of Raleigh, Raleigh
Accellacare Research of Wilmington, Wilmington

Ap rekriteFaz 3

Laj 18 a 99 · Tout sèks · Mizajou Aug 27, 2026 · NCT07575399

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

Research Site, Statesville

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT07784725

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Piedmont Healthcare/Research, Statesville

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT07509307

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

ACCOMPLISH-1 Research Site, Charlotte
ACCOMPLISH-1 Research Site, Durham
ACCOMPLISH-1 Research Site, Fayetteville
ak 3 plis

Ap rekriteFaz 3

Laj 18 a 79 · Tout sèks · Mizajou Aug 10, 2026 · NCT07654361

Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

Monroe Biomedical Research, LLC, Monroe
Accellacare, Wilmington

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Jun 25, 2026 · NCT07607587

A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.

Monroe Biomedical Research, Monroe

Ap rekriteFaz 2

Laj 18 a 60 · Tout sèks · Mizajou Jun 22, 2026 · NCT07570758

Pregnancy Exercise Mode Effect on Childhood Obesity

East Carolina University, Greenville

Ap rekriteVolontè an sante akeyi

Laj 18 a 45 · Fanm · Mizajou Jun 4, 2026 · NCT04805502

NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks

Wake Forest University Health Sciences, Winston-Salem

Ap rekriteVolontè an sante akeyi

Laj 18 a 39 · Fanm · Mizajou Feb 27, 2026 · NCT05674799

A Mobile Intervention to Reduce Pain and Improve Health-III

Wake Forest University, Winston-Salem

Ap rekriteFaz 2

Laj 65 ak plis · Tout sèks · Mizajou Feb 20, 2026 · NCT06623669

MAINTAIN (Mucosal AblatIoN Therapy After INcretins)

True You Weight Loss, Cary
True You Weight Loss, Cary

Ap rekrite

Laj 21 a 65 · Tout sèks · Mizajou Mar 21, 2025 · NCT06734312

REvision of VSG with Ablation of the Mucosa Procedure

True You Weight Loss, Cary

Ap rekrite

Laj 22 a 60 · Tout sèks · Mizajou Nov 5, 2024 · NCT06671119

Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.